|
|
 Previous Article | Table of Contents | Next Article 
Increased expression of the multidrug resistance-associated protein gene in
relapsed acute leukemia
E Schneider, KH Cowan, H Bader, S Toomey, GN Schwartz, JE Karp, PJ Burke and SH Kaufmann
Medicine Branch, National Cancer Institute, Bethesda, MD 20892.
Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was
used to determine relative levels of transcripts for MDR1 and the recently
described multidrug resistance-associated protein (MRP) in normal
lymphohematopoietic cells and in 62 bone marrow aspirates of newly
diagnosed and recurrent acute leukemia. Levels of MRP expression in newly
diagnosed AML samples were similar to those observed in normal bone marrow
cells (CD34-negative and CD34-positive) and in unselected HL60 human
promyelocytic leukemia cells, which were used as an internal control
throughout this study. In contrast, samples of AML obtained at the time of
relapse contained approximately twofold higher levels of MRP RNA (P <
.01). Analysis of paired samples, the first obtained at diagnosis and the
second at relapse, from 13 acute myelogenous leukemia (AML) and four acute
lymphocytic leukemia (ALL) patients showed that MRP expression was
increased at the time of relapse in greater than 80% of patients. In
contrast, no consistent changes of MDR1 expression at relapse were
observed. These results raise the possibility that increased MRP expression
might contribute to leukemic relapse.
Volume 85,
Issue 1,
pp. 186-193,
01/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. L. Greenberg, S. J. Lee, R. Advani, M. S. Tallman, B. I. Sikic, L. Letendre, K. Dugan, B. Lum, D. L. Chin, G. Dewald, et al.
Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)
J. Clin. Oncol.,
March 15, 2004;
22(6):
1078 - 1086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Del Poeta, A. Venditti, M. I. Del Principe, L. Maurillo, F. Buccisano, A. Tamburini, M. C. Cox, A. Franchi, A. Bruno, C. Mazzone, et al.
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)
Blood,
March 15, 2003;
101(6):
2125 - 2131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Feuring-Buske, A. E. Frankel, R. L. Alexander, B. Gerhard, and D. E. Hogge
A Diphtheria Toxin-Interleukin 3 Fusion Protein Is Cytotoxic to Primitive Acute Myeloid Leukemia Progenitors But Spares Normal Progenitors
Cancer Res.,
March 1, 2002;
62(6):
1730 - 1736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ohno, A. Tani, Z.-S. Chen, K. Uozumi, S. Hanada, S. Akiba, X.-Q. Ren, T. Furukawa, T. Sumizawa, T. Arima, et al.
Prognostic Significance of Multidrug Resistance Protein in Adult T-cell Leukemia
Clin. Cancer Res.,
October 1, 2001;
7(10):
3120 - 3126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Feuring-Buske and D. E. Hogge
Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38{-} progenitor cells from patients with acute myeloid leukemia
Blood,
June 15, 2001;
97(12):
3882 - 3889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Baer, C. C. Stewart, R. K. Dodge, G. Leget, N. Sule, K. Mrozek, C. A. Schiffer, B. L. Powell, J. E. Kolitz, J. O. Moore, et al.
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
Blood,
June 1, 2001;
97(11):
3574 - 3580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takemura, Y. Urasaki, A. Yoshida, T. Fukushima, and T. Ueda
Simultaneous Treatment with 1-{beta}-D-Arabinofuranosylcytosine and Daunorubicin Induces Cross-Resistance to Both Drugs due to a Combination-specific Mechanism in HL60 Cells
Cancer Res.,
January 1, 2001;
61(1):
172 - 177.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. M. van der Kolk, E. G. E. de Vries, W. L. J. van Putten, L. F. Verdonck, G. J. Ossenkoppele, G. E. G. Verhoef, and E. Vellenga
P-glycoprotein and Multidrug Resistance Protein Activities in Relation to Treatment Outcome in Acute Myeloid Leukemia
Clin. Cancer Res.,
August 1, 2000;
6(8):
3205 - 3214.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider
Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux
Cancer Res.,
July 1, 2000;
60(13):
3514 - 3521.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. E.P. Smeets, R. A.P. Raymakers, G. Vierwinden, A. H.M. Pennings, H. Wessels, and T. de Witte
Triggering Noncycling Hematopoietic Progenitors and Leukemic Blasts to Proliferate Increases Anthracycline Retention and Toxicity by Downregulating Multidrug Resistance
Blood,
October 1, 1999;
94(7):
2414 - 2423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.-P. Marie
Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia
Blood,
August 1, 1999;
94(3):
1046 - 1056.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Leith, K. J. Kopecky, I-M. Chen, L. Eijdems, M. L. Slovak, T. S. McConnell, D. R. Head, J. Weick, M. R. Grever, F. R. Appelbaum, et al.
Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study
Blood,
August 1, 1999;
94(3):
1086 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Advani, H. I. Saba, M. S. Tallman, J. M. Rowe, P. H. Wiernik, J. Ramek, K. Dugan, B. Lum, J. Villena, E. Davis, et al.
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
Blood,
February 1, 1999;
93(3):
787 - 795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Legrand, G. Simonin, J.-Y. Perrot, R. Zittoun, and J.-P. Marie
Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients
Blood,
June 15, 1998;
91(12):
4480 - 4488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.L. den Boer, R. Pieters, K.M. Kazemier, M.M.A. Rottier, C.M. Zwaan, G.J.L. Kaspers, G. Janka-Schaub, G. Henze, U. Creutzig, R.J. Scheper, et al.
Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia
Blood,
March 15, 1998;
91(6):
2092 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Kaufmann, J. E. Karp, P. A. Svingen, S. Krajewski, P. J. Burke, S. D. Gore, and J. C. Reed
Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse
Blood,
February 1, 1998;
91(3):
991 - 1000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Frankel, P. D. Hall, C. Burbage, J. Vesely, M. Willingham, K. Bhalla, and R. J. Kreitman
Modulation of the Apoptotic Response of Human Myeloid Leukemia Cells to a Diphtheria Toxin Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein
Blood,
November 1, 1997;
90(9):
3654 - 3661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Zhan, V. A. Sandor, E. Gamelin, J. Regis, B. Dickstein, W. Wilson, A. T. Fojo, and S. E. Bates
Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay
Blood,
May 15, 1997;
89(10):
3795 - 3800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Loe, K. C. Almquist, S. P. C. Cole, and R. G. Deeley
ATP-dependent 17beta-Estradiol 17-(beta-D-Glucuronide) Transport by Multidrug Resistance Protein (MRP)
J. Biol. Chem.,
April 19, 1996;
271(16):
9683 - 9689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
